title: [Measurement of bone mineral density is necessary for monitoring of bisphosphonate treatment].
abstract: The treatment efficacy of antiresorptive therapy, including bisphosphonates, is not fully accounted for by change in bone mineral density (BMD). The 1-year increases in hip BMD were reported to be associated with a reduction in spine fracture by using the data from FIT trial, but the changes in spine BMD that was greater than hip BMD were not associated with the risk of spine, non-spine, or hip fracture. On the other hand, the diagnosis of osteoporosis is made mainly by measurement of BMD. In this sense, BMD measurement is thought to be useful in will improvement for the treatment of the patients.
authors.affiliation: Department of Orthopaedic Surgery and Rheumatology, Nara Hospital, Kinki University School of Medicine.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Soen
mesh_terms: D019386:Alendronate / Q000627:therapeutic use; D015415:Biomarkers; D015519:Bone Density; D004164:Diphosphonates / Q000627:therapeutic use*; D016903:Drug Monitoring; D005598:Fractures, Spontaneous / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D010024:Osteoporosis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism*; D012306:Risk; D016103:Spinal Fractures / Q000209:etiology / Q000517:prevention & control*
chemical_list: D015415:Biomarkers; D004164:Diphosphonates; D019386:Alendronate